AtriCure Q3 revenue $83.2M (+18.1% YoY); net loss $0.27/share; guides FY2022 rev ~$328-333M

AtriCure, Inc.

2022-Q3 EPS reported -$0.93 revenue$242,351,000

Revenue $83.2M, up 18.1% YoY (19.8% constant currency). US revenue $69.8M (+21.3%).
Gross margin flat at 74.1%; operating loss $10.7M vs income $98.7M in Q3 2021 (includes non-recurring items).
Adjusted EBITDA negative $0.7M vs positive $0.7M last year; adjusted EPS loss $0.27 vs $0.23.
FY 2022 guidance: revenue ~$328-333M (20-21% growth), adjusted EBITDA loss ~$4M, adjusted loss per share ~$1.10-$1.12.
Growth driven by cryoSPHERE pain management, AtriClip Flex·V, and EnCompass clamp; international growth in Australia and Japan.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AtriCure, Inc. reported the third quarter ended September 30, 2022 results: revenue $83.2 million, EPS $0.27.

Period: the third quarter ended September 30, 2022
Revenue: $83.2 million
EPS: $0.27
Result: reported results

Exact text from the filing

Revenue for the third quarter 2022 was $83.2 million, an increase of 18.1% (an increase of 19.8% on a constant currency basis) over third quarter 2021 revenue.

View on SEC.gov

Browse all earnings releases →

AtriCure, Inc. filing history →

Source: SEC EDGAR

accession 0001323885-22-000113

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.